Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy

Fig. 3

Pretreatment ctDNA level is an independent prognostic biomarker for DLBCL patients (N = 51). A, B Kaplan–Meier estimates of PFS and OS based on pretreatment ctDNA levels. C, D Multivariable cox proportional hazard models of PFS and OS based on pretreatment ctDNA levels and other survival predictors. E, F Kaplan–Meier estimates showing the impact of pretreatment ctDNA levels on PFS and OS in patients with III–IV stage (N = 38). PFS, progression-free survival; OS, overall survival; hGE, haploid genome equivalents; HR, hazard ratio; COO, cell of origin; LDH, lactate dehydrogenase

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us